The Mediterranean School of Oncology

43th course

“Highlights in the management of colorectal cancer”

Rome, 1-2 February 2007

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

The Mediterranean School of Oncology

An educational program of:

Bologna

Chieti-Pescara

Ferrara

Catanzaro Palermo

Roma La Sapienza

Napoli Federico II

Perugia

Ancona

Teramo

L’Aquila

A Consortium among 14 Italian Universities

Foggia

Messina

CARCINOMA DEL COLON-RETTOSCENARIO GLOBALE

2a causa di morte per cancro nei paesi occidentali!

• ~1,000,000 nuovi casi ~ 500,000 decessi/anno

Alla diagnosi:

• 70-80% malattia localizata, resecabile• 50% stadio II • 35% stadio III

• ~40% (~400,000/anno) ripresa di malattia dopo chirurgia potenzialmente curativa

5-FU

Infusionecontinua

Levamisole LD leucovorin

HD leucovorin

Bolus

Anni ’90: ottimizzazione del 5-FU

Sopravvivenza mediana CRC metastatico, Ia linea

Best supportive care

0 6 12 18 24

Median overall survival (months)

~4–6 months

12–14 months5-FU/LV

19–20 monthsFOLFOX4 or CAPEOX

~15–16 monthsIFL or FOLFIRI

20.6 monthsFOLFOX6 FOLFIRI

18.3 months5-FU/LV +

bevacizumab

25.1 monthsIFL + BV OX

20.3 monthsIFL + bevacizumab

Nel 2007, cosa si può attendere un paziente affetto da carcinoma metastatico del colon-retto?

Soparvvivenza globale :24-26+ mesi

Risposte oggettive :50-70%

Tempo alla progressione :8-11+ mesi

Oltre la I linea

Ia lineaFOLFOX + Bevacizumab

IIIa lineaCetuximab +Irinotecan

IIa lineaIrinotecan + 5-FU(Bevacizumab)

Va lineaFOLFOX + Cetuximab

IVa lineaCetuximab + Bevacizumab+ Irinotecan

VIa lineaFOLFOX + Cetuximab +Bevacizumab

VIIa lineaXX +YY

………….………….

Come identificare i pazienti R e NR alla terapia?

50

100

0

25

75

CRC – Criteri di selezione usuali

100 pazienti trattati con CTdopo 5 anni:

70 sono viventi anche senza CT (o-treated)

20 sono deceduti nonostante la CT

Usando il profilo d’espressione genica

Only 22.5% of pts will be overtreated

Patient goes to

Familiy doctor/health center Population-based screening

Investigations &diagnostic testing

Cancer diagnosed Cancer not diagnosed

Treatment Palliative care

Continuing treatment

Follow-up Relapse Terminal care

Long-term survival BereavementCure

Two classes:

1. Foreign students (in English);

2. Italian residents

All courses are accredited for CME by Ministero della Salute, Italy or/and ESMO

2000 2002 2003 2004

2

4

6

8

10Courses/year

Students/year

200

500

300

400

600

0 0

By December 2006:

42 courses>2200 students

2001 2005 2006

Scholarships

Available to candidates <30 years of age.

To apply for a scholarship:

• a brief curriculum vitae;• a letter of presentation from an authorised officer at the institute of affiliation. 

For information:

www. unich.it/mso.cinbo

MSO - 2007 Course Calendar

1-2 February :Highlights in the management of colorectal cancer (E)

16-17 February :Tumori del rene e melanoma: progressi della ricerca traslazionale e clinica

19-20 March :Cardiotossicità da farmaci antitumorali: basi genetiche, diagnosi,

prevenzione e terapia

18-19 April :Highlights in the management of breast cancer (E)

25-26 May :Presente e futuro della terapia del dolore neuropatico in oncologia

8-9 June :Personalized diagnostic and therapeutic strategies in oncology (E)

20-21 July :Sessualità e cancro

5-6 October    :I tumori dell’ovaio 26-27 October :New oncology drugs pipeline update: from bench to bedside (E) 23-24 November :Controversie in oncologia

(E) Courses in English

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

A MSO/CINBO’s pilot project

The “Formazione a Distanza inOncologia” (FADO) Program

FADO Program

Teaching is made via satellite technology.

Designed to build or enhance professional knowledge, skills, and leadership in oncology and related disciplines through distance/online education & training.

Target audience

1. Residents in medical oncology;

2. Ph.D. students (Dottorato di Ricerca) in oncology and related disciplines

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

FADO - Partners

Technologies & services:

Organization & management:

QuickTime™ e undecompressore TIFF (LZW)

sono necessari per visualizzare quest'immagine.

Consorzio Interuniversitario Nazionale per la Bio-Oncologia

A MSO/CINBO’s pilot project

The Mediterranean Task Forcefor Cancer Control (MTCC)

• courses in modular print format• videoconferences;• lectures-seminars-lessons;

To provide a forum for

“distance learning discussion among CINBO member Universities and selected medical Institutions within the mediterranean area”

MTCC“An innovative project to raise awarenessabout cancer prevention and early detection via satellite technology”

Algeria Croatia Egypt France Greece

Italy Jordan Lebanon Lybia Morocco

Portugal Syria Slovenia Spain Tunisia Turkey

Palestine

1st Meeting of the Mediterranean Task Force for Cancer Prevention and Early Detection

October 4th, 2005Taormina, Italy

With the participation of delegates from:

Albania